Editorial
doi: 10.1016/j.jhep.2010.04.014.
Epub 2010 May 31.
Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa
- PMID: 20561707
- DOI: 10.1016/j.jhep.2010.04.014
Item in Clipboard
Editorial
Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa
J Hepatol.
2010 Sep.
Free article
No abstract available
Comment on
-
Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.J Hepatol. 2010 Sep;53(3):460-7. doi: 10.1016/j.jhep.2010.03.019. Epub 2010 May 27. J Hepatol. 2010. PMID: 20561702 Free PMC article.
Similar articles
-
Reply to issues raised in the Jansen/Reesink editorial.J Hepatol. 2007 Feb;46(2):350-1. doi: 10.1016/j.jhep.2006.11.003. Epub 2006 Nov 27. J Hepatol. 2007. PMID: 17161883 No abstract available.
-
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.Antivir Ther. 2008;13(4):511-7. Antivir Ther. 2008. PMID: 18672529 Clinical Trial.
-
Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).Semin Liver Dis. 2004;24 Suppl 2:33-8. doi: 10.1055/s-2004-832926. Semin Liver Dis. 2004. PMID: 15346244 Review.
-
Hepatitis C virus kinetics in chimeric mice during antiviral therapy.Hepatology. 2007 Dec;46(6):2048-9; author reply 2049-50. doi: 10.1002/hep.21798. Hepatology. 2007. PMID: 17935224 No abstract available.
-
A perspective on modelling hepatitis C virus infection.J Viral Hepat. 2010 Dec;17(12):825-33. doi: 10.1111/j.1365-2893.2010.01348.x. Epub 2010 Aug 15. J Viral Hepat. 2010. PMID: 20723038 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
